View Older Stories View More Recent Stories

Apr 24, 2023 07:03AM Foghorn Therapeutics Inc. (FHTX) Pauses Enrollment in FHD-609 Study
Apr 24, 2023 07:00AM Foghorn Therapeutics Provides an Update on FHD-609
Apr 24, 2023 07:00AM Foghorn Therapeutics Provides an Update on FHD-609
Apr 10, 2023 04:05PM Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023
Apr 10, 2023 04:05PM Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023
Apr 6, 2023 04:05PM Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Apr 6, 2023 04:05PM Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Mar 9, 2023 07:00AM Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
Mar 9, 2023 07:00AM Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
Mar 1, 2023 08:00AM Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
Mar 1, 2023 08:00AM Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
Jan 9, 2023 07:00AM Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
Jan 9, 2023 07:00AM Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
Dec 5, 2022 07:00AM Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
Dec 5, 2022 07:00AM Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
Nov 22, 2022 08:00AM Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
Nov 22, 2022 08:00AM Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
Nov 14, 2022 07:00AM Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
Nov 14, 2022 07:00AM Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
Nov 9, 2022 07:00AM Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
Nov 9, 2022 07:00AM Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
Nov 8, 2022 07:00AM Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
Nov 8, 2022 07:00AM Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
Oct 27, 2022 07:03AM Foghorn Therapeutics Inc. (FHTX) Appoints Dr. Thomas J. Lynch, Jr. to Its Board
Oct 27, 2022 07:00AM Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
Oct 27, 2022 07:00AM Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
Oct 26, 2022 07:04AM Foghorn Therapeutics Inc. (FHTX) Announces New BRD9 Data
Oct 26, 2022 07:00AM Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
Oct 26, 2022 07:00AM Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
Oct 20, 2022 07:00AM Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
Oct 20, 2022 07:00AM Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
Sep 27, 2022 08:00AM Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
Sep 27, 2022 08:00AM Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
Sep 1, 2022 04:05PM Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Sep 1, 2022 04:05PM Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Aug 31, 2022 04:06PM Foghorn Therapeutics Inc. (FHTX) Announces Board Changes
Aug 31, 2022 04:05PM Foghorn Therapeutics Announces Change to Board of Directors
Aug 31, 2022 04:05PM Foghorn Therapeutics Announces Change to Board of Directors
Aug 23, 2022 07:00AM Foghorn Therapeutics Inc. (FHTX) Announces FDA Clinical Hold Placed on FHD-286 Phase I Study
Aug 23, 2022 07:00AM Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
Aug 23, 2022 07:00AM Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
Aug 17, 2022 07:02AM Foghorn Therapeutics Inc. (FHTX) Elects Lynne Parshall to its Board
Aug 17, 2022 07:00AM Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
Aug 17, 2022 07:00AM Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
Aug 16, 2022 07:00AM Senda Biosciences Announces Close of $123 Million Series C Financing
Aug 9, 2022 07:00AM Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
Aug 9, 2022 07:00AM Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
Aug 1, 2022 08:00AM Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Aug 1, 2022 08:00AM Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Mar 23, 2022 04:00AM ONK Therapeutics Brings in US Financial Experience with the Appointment of Dr. Allan Reine as Independent Non-Executive Director
View More Recent Stories View Older Stories